Ace Vision Group
Ace Vision Group is an emerging ophthalmic laser device company headquartered in Boston, MA, pioneering a new rejuvenation therapy for the aging eye called Laser Scleral Microporation (LSM). The company is conducting clinical trials for its LSM treatment and VisioLite® Ophthalmic Laser System outside the United States, aiming to address presbyopia, which affects 2.1 billion people worldwide.
Company Overview
Ace Vision Group is an emerging ophthalmic laser device company headquartered at One Boston Place Suite 2600, Boston, MA 02108. The company is pioneering a new rejuvenation therapy for the aging eye. Their mission is to lead in developing innovative touchless Microporation Therapeutics to combat age-related vision loss. Ace Vision Group aims to offer eye care professionals cutting-edge devices, procedures, and education for the prevention and recovery of vision deterioration.
Presbyopia and Its Global Impact
Presbyopia is an age-related condition that affects 2.1 billion people worldwide, causing blurry near vision. As people age, the scleral tissue in the eye becomes stiff, leading to a loss of the eye's natural Dynamic Range of Focus (DRoF). Ace Vision Group's mission is to address this significant global issue through innovative therapeutic solutions.
Laser Scleral Microporation (LSM)
Laser Scleral Microporation (LSM) is a novel therapeutic procedure developed by Ace Vision Group to treat presbyopia. The LSM treatment is designed to rejuvenate the eye by creating micropores in the scleral tissue, thereby restoring the eye’s natural dynamic mechanisms of accommodation and disaccommodation. This treatment does not interfere with the visual axis and allows the natural dynamic mechanism of the eye to function effectively.
VisioLite® Ophthalmic Laser System
The VisioLite® Ophthalmic Laser System is an advanced laser device used in the Laser Scleral Microporation (LSM) procedure. Currently, the VisioLite® system and LSM treatment are in clinical trials and have not yet received FDA approval or become available in the United States. The company is conducting clinical research studies in select areas outside of the United States and expects the laser to be on the pathway to commercialization potentially by the end of the year.
Current Clinical Trials and Research
Ace Vision Group is actively conducting clinical research studies for the LSM procedure at various clinical sites outside of the United States. These trials are essential for evaluating the safety and efficacy of the LSM treatment. If successful, the VisioLite® system and LSM therapy could provide a groundbreaking solution for presbyopic patients, helping to restore their visual function and improve their quality of life.